A genetic risk score based on BCL11A and HBS1L‐MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients
Authors:
- Gabriela S. ArcanjoGAGabriela S. Arcanjo
- Alexsandro P. SilvaASAlexsandro P. Silva
- Madi V. DinizMDMadi V. Diniz
- Igor F. DomingosIDIgor F. Domingos
- Diego A. Pereira‐MartinsDPDiego A. Pereira‐Martins
- Amanda B. AraújoAAAmanda B. Araújo
- Aderson S. AraujoAAAderson S. Araujo
- Edis Belini‐JuniorEBEdis Belini‐Junior
- Sara T. O. SaadSSSara T. O. Saad
Open Access
- 16 April 2026
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2203-2211
Abstract
Summary: Individuals with sickle cell anaemia (SCA) exhibit significant clinical heterogeneity influenced by several factors, especially fetal haemoglobin (HbF) levels. Variations in adult HbF levels are partly explained by the co‐inheritance of genetic variants that regulate globin expression. In this study, we investigated the association of BCL11A rs4671393, rs1427407, rs11886868 and HBS1L‐MYB rs9399137 polymorphisms with HbF levels and clinical complications in a cohort of 409 adult Brazilian SCA patients. Our findings reveal that variant alleles of all four single‐nucleotide polymorphisms (SNPs) were significantly associated with higher HbF levels. Moreover, homozygosity for the major alleles was independently associated with higher risk and cumulative incidence of stroke, avascular necrosis, leg ulcers, priapism and acute chest syndrome. Haplotype analysis with BCL11A variants was also associated with HbF and the patient's phenotype. A genetic risk score (GRS) combining the risk genotypes was significantly associated with lower HbF levels ( p < 0.0001) and increased complication risk ( p < 0.0001). A model integrating the GRS with clinical variables demonstrated superior discriminatory performance (area under the curve (AUC): 0.72) compared to models based solely on clinical factors. In summary, this study underscores the clinical relevance of HbF‐related genetic variants and supports their integration into risk stratification and personalized management strategies for SCA.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (405918/2022‐4)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (408710/2021‐7)
- Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (APQ‐1212‐2.02/22)
This publication has 41 references indexed in Scilit:
- Genetic Variation and Sickle Cell Disease SeverityJAMA Network Open, 2023
- MYB – A regulatory factor in hematopoiesisGene, 2018
- Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin SwitchCell, 2018
- DNA polymorphisms at BCL11A, HBS1L-MYB and Xmn1-HBG2 site loci associated with fetal hemoglobin levels in sickle cell anemia patients from Northern BrazilBlood Cells, Molecules, and Diseases, 2014
- Data quality control in genetic case-control association studiesNature Protocols, 2010
- Hydroxyurea for the Treatment of Sickle Cell AnemiaNew England Journal of Medicine, 2008
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15Nature Genetics, 2007
- Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adultsProceedings of the National Academy of Sciences, 2007
- ß s -Gene-Cluster Haplotypes in Sickle Cell Anemia: Clinical and Hematologic FeaturesHematology/Oncology Clinics of North America, 1991